Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOOST: IDegAsp vs BIAsp 30 in T2D
NCT01513590Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2012
- Primary completion
- Nov 2012
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change From Baseline in HbA1c (Glycosylated Haemoglobin) at 26 weeks. Started Jan 2012; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01513590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01513590.